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Background: New interferon (IFN)-free treatments for hepatitis C are more effective, safer but more expensive than
current IFN-based therapies. Comparative data of these, versus current first generation protease inhibitors (PI) with
regard to costs and treatment outcomes are needed. We investigated the real-world effectiveness, safety and cost
per cure of 1st generation PI-based therapies in the UK.
Methods: Medical records review of patients within the HCV Research UK database. Patients had received
treatment with telaprevir or boceprevir and pegylated interferon and ribavirin (PR). Data on treatment outcome,
healthcare utilisation and adverse events (AEs) requiring intervention were collected and analysed overall and by
subgroups. Costs of visits, tests, therapies, adverse events and hospitalisations were estimated at the patient level.
Total cost per cure was calculated as total median cost divided by SVR rate.
Results: 154 patients from 35 centres were analysed. Overall median total cost per cure was £44,852 (subgroup
range,: £35,492 to £107,288). Total treatment costs were accounted for by PI: 68.3 %, PR: 26.3 %, AE management:
5.4 %. Overall SVR was 62.3 % (range 25 % to 86.2 %). 36 % of patients experienced treatment-related AEs requiring
intervention, 10 % required treatment-related hospitalisation.
Conclusions: This is the first UK multicentre study of outcomes and costs of PI-based HCV treatments in clinical
practice. There was substantial variation in total cost per cure among patient subgroups and high rates of
treatment-related discontinuations, AEs and hospitalisations. Real world safety, effectiveness and total cost per cure
for the new IFN free combinations should be compared against this baseline.
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Hepatitis C virus (HCV) infection remains a global pub-
lic health issue with most recent estimates suggesting
that more than 180 million people have been infected
worldwide [1]. The combination of peginterferon alfa
(IFN), ribavirin (RBV) and one of the first generation
protease inhibitors (PI), boceprevir (BOC) or telaprevir
(TVR) was the standard care for genotype 1 HCV up to
2014 [2, 3].
IFN based HCV treatment is able to cure HCV (as de-
fined by sustained virological response, SVR) [2] which
is associated with improved clinical outcomes [4–6].* Correspondence: will.irving@nottingham.ac.uk
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(http://creativecommons.org/publicdomain/zeHowever, common adverse events (AEs) associated with
traditional 1st generation PI-based therapies include
skin rashes, pruritus, anaemia, neutropaenia, nausea
and dysgeusia [7]. In addition, treatment with IFN may
cause psychiatric adverse events such as depression [8].
Evidence suggests that treatment-related AEs have
a negative impact on health-related quality of life
(HRQoL) leading to higher rates of premature discon-
tinuation and lower SVR rates than reported from
clinical trials [9, 10]. Evidence from clinical trials sug-
gests that in treatment naïve genotype 1 patients, triple
therapy of PR + 1st generation PIs results in SVR rates
of between 65–75 % [11–14] however, lower effective-
ness has been reported in real-world studies (44–55 %)
[15–18].is distributed under the terms of the Creative Commons Attribution 4.0
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with the emergence of novel highly effective all oral
combination therapies active against genotype 1 [2].
With better efficacy, improved safety and substantially
shortened treatment durations, these IFN – and RBV-
free treatments are expected to become the cornerstone
of HCV therapy, [19–23]; these advances represent a
major treatment improvement for patients. However,
current pricing, combined with the likely increased pa-
tient demand, means these regimens pose a significant
budgetary impact in developed healthcare systems [24].
Recently, the concept of “cost per SVR” has evolved to
take account of opportunity costs (i.e. the loss of poten-
tial gain from other alternatives when one alternative is
chosen) in HCV management. More data is required to
understand the total cost per SVR of existing IFN-based
therapies to allow meaningful comparison with newer
interferon free regimens.
To date there have been no published real-world
studies assessing the cost per cure, safety and effect-
iveness of PR + 1st generation PI triple therapy in the
UK. This study aimed to estimate the total cost per
HCV patient cured associated with first generation
PI-based therapy in a real world setting, across a
large number of centres. As secondary objectives, this
study also aimed at estimating the effectiveness, safety
and tolerability of these regimens.
Methods
Study design and patients
This was a retrospective observational multi-centre
study of patients enrolled in the HCV Research UK bio-
bank, who received a first generation PI-based regimen
between July 2012 and July 2014 through National
Health Service (NHS) hospitals following recommenda-
tion by the National Institute for Health and Care Excel-
lence (NICE) [25, 26] and the Scottish Medicines
Consortium. HCV Research UK is a cohort of 10,000 pa-
tients, plus database and biorepository, enrolled with in-
formed consent from 59 centres across England,
Scotland and Wales [27]. Patients within HCV Research
UK were considered eligible for this analysis if they were
18 years of age or older, had HCV genotype 1 infection
and had received either TVR or BOC in association with
PEG + RBV with a known treatment outcome. Patients
were randomly selected for this study from all eligible
patients using a number generator. A TVR: BOC sample
ratio of 2:1 was chosen to reflect use in clinical practice
among the HCV Research UK cohort.
Data collection
Baseline data available from within the HCV Research UK
database were supplemented by a detailed clinic case note
review. Data collected included patient characteristics atinitiation of the PI-based treatment (age, gender, ethnicity,
liver disease status, genotype, blood test results, comor-
bidities recorded in the HCV Research UK database relat-
ing to renal failure, diabetes, HIV co-infection, depression,
haemophilia and cancer (other than HCC)), previous
HCV therapy (type of treatment and associated response),
details regarding the PI-based therapy, treatment out-
come, safety and healthcare resource use (nurse and phys-
ician visits, tests and investigations, medications used to
treat AEs, and hospitalisations). Details on comorbidities
at baseline were gathered through a review of the patient’s
clinical notes as well as patient questionnaire. IL28B geno-
typing at locus rs12979860 was performed (by Micro-
pathology Ltd, Coventry, UK) post-hoc using a Roche
Hybprobe kit and meltcurve analysis.
Assessment of outcomes
The outcomes of interest included SVR, which was
assessed at 12 or 24 weeks. The incidence and type of
adverse events (AEs) requiring therapeutic intervention,
healthcare resource use, treatment discontinuation and/
or hospitalisation was collected by the study centre
through a standardised questionnaire and quality con-
trolled by a study coordinator. The relationship of HCV
therapy to each AE was assessed independently by two
physicians (STB, GSC), and categorised as “likely”, “un-
likely” or “can’t tell”. Any discrepancy between assess-
ments was resolved by discussion. In total, there were 12
discrepancies after the initial individual assessments, all
of which were agreed on after discussion with no further
action needed.
Costs were estimated from the NHS perspective.
The unit costs to be applied were derived from the
British National Formulary for drugs [28]. The cost of
managing HCV was estimated by applying the na-
tional unit costs to the number of physician and
nurse visits, medications and tests [29]. The cost of
hospitalisations was estimated based on Health Re-
source Group (HRG) codes classifying the reasons for
hospitalisation and procedures undertaken during the
stay [30]. Corresponding unit costs were obtained
from the NHS reference costs [31]. Total costs were
estimated and cost per cure was calculated as total
median cost divided by SVR rate. For the conversion
of UK pound (£) to US dollar ($), the Bank of England
exchange rate was applied (£1 = $1.4905) [32].
Statistical analysis
Sample size was not formally assessed and the number
of patients enrolled was based on time and resource
constraints. Descriptive statistics were analysed accord-
ing to treatment status (naïve vs experienced) and liver
disease status (cirrhosis vs no cirrhosis) at baseline. The
proportion of patients achieving SVR was determined
Table 1 Baseline characteristics for total cohort
All patients (n = 154)
Age [Mean, (SD)] 49.6 (9.01)
Gender
Male [%] 73.4 %
Female [%] 26.6 %
Ethnicity
White [%] 94.2 %
Liver disease (Metavir stage)
Non-cirrhotic (F0-F3) [%] 78.6 %
Cirrhotic (F4 including 1 HCC) [%] 21.4 %
Treatment history
Experienced [%] 52.0 %
Naïve [%] 48.0 %
Response to previous therapy
Relapse [%] 43.7 %
No response [%] 45.0 %
Missing [%] 11.3 %
HCV genotype
Genotype 1a [%] 51.3 %
Genotype 1b [%] 18.8 %
G1 subtype Missing [%] 29.9 %
HCV therapy
Telaprevir treatment [%] 69.1 %
Boceprevir treatment [%] 33.1 %
IL28B status (SNP rs12979860)
Heterozygous CT [%] 56.9 %
Homozygous CC [%] 29.4 %
Homozygous TT [%] 13.7 %
Missing [%] 0.7 %
Comorbidities
Depression [%] 26.0 %
HIV co-infection [%] 6.5 %
Diabetes [%] 5.2 %
Haemophilia [%] 5.2 %
Cancer [%] 3.9 %
Renal failure [%] 0.7 %
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status. The calculation of SVR took into account all pa-
tients, including those who discontinued therapy prema-
turely. The statistical significance was tested for each
comparison using a Chi-square test.
Logistic regression was conducted to assess the impact
of patient characteristics on the probability of reaching
SVR. The list of covariates was specified a priori and in-
cluded age, liver disease status, gender, treatment naïve vs
experienced, HIV co-infection, IL28B subtypes, history of
depression, diabetes, genotype and race. A stepwise pro-
cedure was run to identify the most significant covariates.
The incidence of AEs and of AEs assessed as “likely”
to be related to HCV treatment was estimated overall
and by type of AE. The incidence of AEs leading to
treatment discontinuation and/or to hospitalisation was
also estimated.
To identify factors which have an impact on the prob-
ability of experiencing an AE, a logistic regression was
conducted. The list of covariates included age, gender,
treatment regimen, past treatment history, liver disease
status, HIV status, history of depression and diabetes.
Sensitivity analyses were performed to assess the im-
pact of PI drug price discounts of 30 %, 40 % and 50 %
and the impact of including management costs of ‘can’t
tell’AEs on the total cost per cure.
Results
Baseline characteristics
From the initial 160 patients selected for this study from
the HCV Research UK database, 8 patients did not in fact
start TVR/BOC therapy, 3 patients were switched from one
PI to the other, 1 patient had a genotype 3 infection, and
for 5 patients, the clinics concerned notified us that they
would not be able to retrieve and return the data within
our specified timeframe, resulting in a total of 17 patients
being excluded. An additional 11 patients were randomly
selected, resulting in a total of 154 patients entered into this
study derived from 35 centres.
Table 1 shows the baseline characteristics of all pa-
tients enrolled in this study. Of all patients, 63/154
(40.9 %) had at least one comorbidity and 8/154 (5.2 %)
had at least two. The most common comorbidities at
baseline were reported history of depression (40/154,
26 %), HIV co-infection (10/154, 6.5 %), diabetes (8/154,
5.2 %), haemophilia (8/154, 5.2 %), cancer (6/154, 3.9 %)
and renal failure (1/154, 0.7 %). Over half the patients
were treatment experienced (80/154, 52 %), the majority
having been treated with PEG + RBV (62/80, 77.5 %).
The nature of the previous treatment regimen was not
available for the other 18 patients. Among treatment-
experienced patients, 35/80 (43.7 %) were relapsers and
36/80 (45.0 %) were non-responders. This information
was not available for 9 patients.More treatment-experienced patients had cirrhosis
compared to treatment-naïve (24/80 (30.0 %) vs 9/74
(12.2 %); p = 0.007). Patients with cirrhosis were signifi-
cantly older than those with milder liver disease (stages
F0 – F3) (55.6 years (SD: 7.16) vs 48.1 years (SD: 8.9);
p < 0.0001).
Effectiveness results
Overall 96/154 (62.3 %) patients achieved SVR. SVR rate
in patients treated with BOC was 63.1 % (65/103) and
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The SVR rate among patients who were treatment-naïve
was 51/74 (68.9 %) compared to 12/36 prior non- re-
sponders (33.3 %; p = 0.004, Table 2). Patients with cir-
rhosis showed consistently lower SVR compared to
those with milder liver disease regardless of previous
treatment status. The logistic regression found age, cir-
rhotic status and IL28b genotype to be significant pre-
dictors of SVR (Table 3). Patients with cirrhosis were
almost 3 times less likely to achieve SVR compared to
those with milder liver disease (F0 – F3) (OR = 0.35;
95 %CI: 0.13, 0.94). Patients with a CC genotype of
IL28b were around 9 times more likely to achieve SVR
than those with non-CC genotype (OR = 0.116; 95 %CI:
0.037, 0.365).
Safety analysis
Over the study period 70/154 (45 %) of the study popu-
lation experienced at least one AE requiring interven-
tion. The total number of AEs requiring intervention
was 178 (see Additional file 1 for details). 141/178
(79.2 %) of these were assessed as “likely” to be related
to treatment. Twenty-two of the 178 (12.4 %) AEs re-
quiring intervention were due to anaemia. This was
managed by ribavirin dose reduction (16/22, 72.7 %),
treatment with erythropoietin analogues (6/22, 27.3 %)
and/or blood transfusion (15/22, 68.2 %). All the patients
who required intervention for neutropaenia, (n = 6)
were treated with GCSF, and the single case of
thrombocytopenia (n = 1) was managed with a dose
reduction.
Fifty-five out of 154 (33 %) patients stopped therapy
prematurely – of those 17/55 (30.9 %) because of ad-
verse events, 24/55 (43.6 %) patients failed stopping
rules, 12/55 (21.8) patients withdrew themselves from
therapy, and for 2/55 (3.6 %) patients the physician with-
drew therapy. There were 36 hospitalisations amongst
29 patients and, of those, 16 (44.4 %) hospitalisations
were classified as “likely” to be treatment related, com-
prising of 15 hospitalisations due to anaemia (all were
associated with blood transfusion) and 1 due to severe
headache (see Supplementary material).Table 2 SVR rate by regimen, cirrhosis status and prior treatment hi
Total (n = 145a) Treatment-naïve patients (n = 74)
SVR rate 68.9 % [57.1;79.2]
By regimen
BOC triple therapy (n = 48) 66.7 % [47.2;82.7] (n = 30)
TVR triple therapy (n = 97) 70.4 % [54.8;83.2] (n = 44)
By liver disease stage
No-cirrhosis (n = 114) 73.8 % [61.5;84.0] (n = 65)
Cirrhosis or HCC (n = 31) 33.3 % [7.5;70.1] (n = 9)
a Previous treatment outcome status was not available for 9 patientsUsing logistic regression, liver disease status, treatment
regimen, gender and past treatment experience were
statistically significant predictors of the incidence of any
AE (see Supporting material). Cirrhotic patients had a
3-fold increased risk of experiencing an AE compared
with patients with no cirrhosis (p = 0.0206). Patients on
TVR were twice as likely to experience an AE compared
to patients on BOC (p = 0.0445). Females had approxi-
mately a 2-fold increased risk of AEs compared to males
(p = 0.0384) as did treatment-naïve patients compared to
experienced patients (p = 0.0476).
Economic assessment
The overall median total cost per HCV cure was £44,852
($66,852). Median cost per HCV cure varied according
to prior treatment status: £83,948 ($125,125) for previ-
ous non-responders, £39,150 ($58,353) for prior re-
lapsers and £37,958 ($56,576) for treatment naïve
patients (Table 4).
Patients with cirrhosis consistently showed higher
costs per cure compared to those with milder liver dis-
ease across subgroups - £61,496 ($91,660) vs £35,492
($52,900) in treatment naïve patients; £49,016 ($73,058)
vs £37,455 ($55,827) in prior relapsers; £107,288
($159,913) vs £73,098 ($108,953) in non-responders.
Using NHS list prices for the base case analysis total dir-
ect cost associated with the management of the 154 HCV
patients was estimated to be £4,289,909 ($6,394,109). The
total drug costs for the 154 patients associated with PI
therapies accounted for 68.3 % of total cost (£2,930,769;
$4,368,311), PEG accounted for 19.5 % (£834,485;
$1,243,800) and RBV, 6.8 % (£290,975; $433,698) (Table 5).
In the base case analysis, ‘other’ costs accounted for 5.4 %
of total costs (£233,780; $348,449), comprising of consult-
ant/nurses visits (59.9 %; £139,992); tests (22.5 %;
£52,616); medications for adverse events (including blood
transfusions) (7.4 %; £17,233); other investigations (6.3 %;
£14,576) and hospitalisations (3.9 %; £9,209) (Table 5).
Management of depression accounted for a small fraction
of these costs.
All but 1 (13/14) patient experiencing a ‘likely’
treatment-related hospitalisation had a single hospitalstory
Prior relapsers (n = 35) Prior non-responders (n = 36)
82.9 % [66.4;93.4] 33.3 % [18.6;51.0]
75.0 % [34.9;96.8] (n = 8) 30.0 % [6.7;65.2] (n = 10)
85.2 % [66.3;95.8] (n = 27) 34.6 % [17.2;55.7] (n = 26)
86.2 % [68.3;96.1] (n = 29) 40.0 % [19.1;64.0] (n = 20)
66.7 % [22.3;95.7] (n = 6) 25.0 % [7.3;52.4] (n = 16)
Table 3 Logistic regression: Probability of achieving SVR
Parameter OR 95 % Wald Confidence Limits Standard Error P value
Age 0.94 0.90 0.99 0.03 0.02
Gender 1.20 0.49 2.93 0.23 0.69
Female (vs male)
Liver disease 0.35 0.13 0.94 0.25 0.04
Cirrhosis (vs no cirrhosis)
Treatment status 0.84 0.35 1.99 0.22 0.69
Experienced (vs naïve)
HIV co-infection (n = 10) 2.56 0.44 14.77 0.45 0.29
Absence (vs presence)
Depression (n = 40) 0.88 0.35 2.22 0.24 0.79
Absence (vs presence)
Diabetes (n = 8) 4.94 0.62 39.56 0.53 0.13
Absence (vs presence)
IL28b 0.12 0.04 0.37 0.29 0.0002
Non-CC (vs CC)
Genotype 1.09 0.37 3.22 0.29 0.28
G1a (vs G1b)
Race 0.31 0.04 2.42 0.52 0.27
Other (vs white)
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mean number of hospital days spent per hospitalisa-
tion was 3.5.
In the UK, treatment is generally supervised by a clin-
ical nurse specialist, however 78/154 (51 %) of patients
had at least one consultant (hepatology or infectious
diseases) visit and 17/154 (11 %) patients required at
least one dermatologist visit during treatment. The mean
number of consultant visits per patient during the
follow-up was 1.2, with a mean number of nurse visits of
14.5. During the follow-up period, patients had, on aver-
age, 13 liver function tests, 10 electrolyte tests and 5
HCV viral load tests. In total ‘other healthcare costs’
accounted for approximately £1,500 per patient; £232,573
per 154 patients.
The PI price sensitivity analysis (30 %, 40 %, 50 % dis-
count) indicated that a 10 % drop in PI drug price was
associated with a decrease of 7 % in the cost per cureTable 4 Cost per HCV cure – by prior treatment and cirrhotic status
Total (n = 154) Treatment naïve patients
(n = 74)
Prior relaps
(n = 35)
Overall £ 37,958 £ 39,150
By liver disease stage
Non cirrhotic (n = 114) £ 35,492 £ 37,455
Cirrhotic (n = 31) £ 61,496 £ 49,016(Table 5). Discount rates sensitivity analyses stratified
according to outcome of previous therapy as well as liver
disease status showed clearly that no response to previ-
ous therapy as well as the presence of cirrhosis is asso-
ciated with increases in total costs per cure (see
Supporting material).
In the base case analysis, only ‘likely’ hospitalisations
and AEs were included. 141 AEs were deemed ‘likely’
and 24 ‘can’t tell’ (the remaining 13 being deemed “un-
likely”). The impact of inclusion of cost for ‘can’t tell’
classified AEs in the sensitivity analysis had only a negli-
gible impact on total median cost per SVR - £38,027 vs
£37,958 with and without respectively.
Discussion
The fact that HCV infection will incur a significant fu-
ture healthcare burden is now commonly accepted. Use
of highly effective therapies has been proven to improveers Prior non-responders
(n = 36)
Prior treatment status unknown
(n = 9)
£ 83,948 £ 61, 804
£ 73,098 £ 49,070
£ 107,288 NA
Table 5 Total costs
Costs Base case Total cost
(in £)
% 30 % discount on PI % 40 % discount on PI % 50 % discount on PI %
PIs 2,930,769 68.3 2,051,538 60.2 1,758,461 56.4 1,465,385 51.9
PegINF 834,485 19.5 834,485 24.5 834,485 26.8 834,485 29.6
Ribavirin 290,975 6.8 290,975 8.5 290,975 9.3 290,975 10.3
Physician visits 139,992 5.4 232,573 6.8 232,573 7.5 232,573 8.2
Tests 52,616
Other investigation 14,576
Hospitalisation 9,209
Adverse events 17,233
Depression & hypnotics 54
Total 4,289,909 100.0 3,409,571 100.0 3,116,494 100.0 2,823,418 100.0
Total median cost per cure (£) 44,852 - 34,416 - 30,968 - 27,233 -
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and mortality [33]. The first IFN-free combinations of
directly acting antivirals (DAAs) against hepatitis C
(HCV) have been licensed and more are likely to follow
in the coming years. These treatments are significantly
shorter in duration, yield higher SVR and have fewer
AEs [34] than traditional IFN-based therapies. With ex-
pected high costs of therapy, it is important to evaluate
the cost per SVR in order to maximise efficient use of
scarce healthcare resources.
We set out to describe the effectiveness, safety and
costs per cure for first generation protease inhibitor
based treatment of genotype 1 hepatitis C (the most
common genotype), in a real-world UK setting.
Differences between SVR results achieved in trials
(efficacy) and those in clinical practice (effectiveness)
with PR + 1st generation PIs have been previously docu-
mented [11–18]. Such differences have been attributed
to the restrictive inclusion criteria of clinical trials with
respect to certain groups of patients including those
with advanced disease, cirrhosis and high co-morbidity
burden.
While we found an overall SVR of 63 % in our sample,
comparable with registration trials, there was (as ex-
pected) significant variation, with cirrhotic patients and
prior non-responders having worse SVR outcomes.
Just over a third (35.7 %) of patients did not complete
treatment. The discontinuation rate due to treatment re-
lated AE amongst our sample was 11 %. Nearly half of
patients in our sample experienced an AE requiring an
intervention with 79 % of those AE considered ‘likely’ to
be treatment-related. Almost 10 % of all patients re-
quired hospitalisation ‘likely’- related to treatment.
Overall median total cost per cure for our sample in
the base case analysis was £44,852; however, there was
substantial variation among subgroups ranging from£35,492 in treatment naive non-cirrhotics to £107,288 in
cirrhotic prior non-responders. In the base case analysis
for 154 patients, HCV triple therapy costs accounted for
94.6 % of the total cost (£4,056,229).
The characteristics of our UK cohort and the overall
SVR rates are very similar to a study carried out in
Germany, although the costs per cure estimated here
were significantly lower, a difference driven to a large
extent by the higher costs attributed to antivirals in
Germany (see Table 6). A recent US study of similar size
found a lower overall SVR rate, reflecting in part a
slightly older population and a higher proportion of
African-Americans, a group where a higher prevalence
of IL28b T allele has been associated with poorer treat-
ment outcomes. Despite these differences, cost per cure
in the US was substantially higher, likely due to sample
differences (e.g. proportion of high cost prior non-
responders 46 % US: 22 % UK) as well as differences in
clinical AE management (e.g. anaemia) and drug costs).
The strength of this study is that it represents a large
randomly drawn sample, representing 35 UK centres
treating hepatitis C, taken from a large UK database
(HCV Research UK) and is thus likely to be representa-
tive of overall UK practice. The overall case-mix of pa-
tients considered for treatment in coming years is likely
to change and the breakdown of outcomes presented ac-
cording to sub-groups allows comparative analysis for
different patient groups.
There are a number of factors which may underesti-
mate the ‘true’ total cost per cure in our analysis. Firstly,
we conducted our analysis from the direct health service
perspective only, we did not consider additional indirect
(such as loss in economic productivity due to treatment
related side effects) or intangible costs (e.g. loss in
HRQoL). Secondly, perhaps of greater impact on the de-
finitive cost-per-cure per patient, we have not taken into
Table 6 Comparison with recent US and German studies
Patients characteristics Current study
(n = 154)
Stahmeyer et al. (GER) [35]
(n = 858)*
Bichoupan et al. (US) [17]
(n = 147)
Age, years [Mean, (SD)] 49.6 (9.0) 49.2 (11.2) 56 (IQR = 51–61)
Gender, Male [%] 73.4 58 68
Ethnicity, %
Caucasian [%] 94.20 % 97.30 % Not reported
Asian [%] 2.70 % 0.90 % Not reported
African [%] 1.30 % 0.80 % 19 %
Hispanic [%] Not reported 0.50 % Not reported
Other [%] 1.80 % Not reported Not reported
SVR rate by therapy
BOC [%] 60.8 58.1 Not reported
TVR [%] 63.1 68.4 44
Cirrhosis [%] 21.40 % Not reported 36 %
Prior non-responders [%] 22.10 % Not reported 46 %
Cost drivers
Drug costs 94.60 % 94.6–97.7 % 89 %
PIs 68.30 % Not reported Not reported
TVR Not reported Not reported 61
PegIFN 19.50 % Not reported 24 %
RBV 6.80 % Not reported 4 %
Outpatient and inpatient care (incl AEs & follow-up) 5.40 % 5.4-3.3 % 8 %
Cost per SVR ($)
Treatment naïve 56,576 73,473–82,756 Not reported
Relapsers 58,353 78,529–93,758 Not reported
Non-responders 125,125 127,1049–132,204 Not reported
Overall Not reported Not reported 189,000
*Costs from Stahmeyer et al. were converted from euros to US dollars (conversion rate: €1 = $1.0985 based on European Central Bank exchange rates,
March 2015)
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patients who failed PI treatment.
Analysis of cost-effectiveness is inevitably something
that will change as prices of drugs, which make up
the bulk of treatment costs, change. It is reasonable
to expect that as there is more competition, prices
will fall. Table 5 shows the effect of discount on cost-
per-cure and given the high proportion of overall
costs due to PI, discounts have a significant impact
on cost-per-cure. However the results also show the
proportional increase of non-discountable ‘other’ (largely
AE management related) healthcare costs. This study
provides valuable data to allow clinicians and health-
care decision makers to evaluate the real world total
cost-per-cure amongst patients treated with current
and future therapies. In particular, we provide a base-
line dataset against which with the total cost per
cure of emerging, all oral therapies can be compared
and contrasted.Conclusion
The future healthcare burden of HCV in the UK, as in
many countries, is significant. Further prospective real
world safety, effectiveness and total cost data is needed for
the new IFN free treatment combinations from different
healthcare settings. Comparison with this data can provide
evidence to inform future treatment decisions to ensure
scarce healthcare resources are able to maximize patient
outcomes.Additional file
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